Immunogenicity and safety of a SARS-CoV-2 N-terminal domain and receptor-binding domain monovalent XBB.1.5 vaccine in Japanese participants.

Grassi CM, Feng J, Wahid R, Kandinov B, Goel S, Wang D, Sellers K, Dixit A, Kogawara O, Das R, Chalkias S

Open source

DOI
10.1016/j.vaccine.2025.127960
Published
2026 Jan 1
Container
Vaccine
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.vaccine.2025.127960,
  title = {Immunogenicity and safety of a SARS-CoV-2 N-terminal domain and receptor-binding domain monovalent XBB.1.5 vaccine in Japanese participants.},
  author = {Grassi CM and Feng J and Wahid R and Kandinov B and Goel S and Wang D and Sellers K and Dixit A and Kogawara O and Das R and Chalkias S},
  year = {2026},
  journal = {Vaccine},
  doi = {10.1016/j.vaccine.2025.127960},
  url = {https://doi.org/10.1016/j.vaccine.2025.127960}
}

RIS

TY  - JOUR
TI  - Immunogenicity and safety of a SARS-CoV-2 N-terminal domain and receptor-binding domain monovalent XBB.1.5 vaccine in Japanese participants.
AU  - Grassi CM
AU  - Feng J
AU  - Wahid R
AU  - Kandinov B
AU  - Goel S
AU  - Wang D
AU  - Sellers K
AU  - Dixit A
AU  - Kogawara O
AU  - Das R
AU  - Chalkias S
PY  - 2026
JO  - Vaccine
DO  - 10.1016/j.vaccine.2025.127960
UR  - https://doi.org/10.1016/j.vaccine.2025.127960
ER  - 

APA

CM, G., J, F., R, W., B, K., S, G., D, W., K, S., A, D., O, K., R, D., & S, C. (2026). Immunogenicity and safety of a SARS-CoV-2 N-terminal domain and receptor-binding domain monovalent XBB.1.5 vaccine in Japanese participants.. Vaccine. https://doi.org/10.1016/j.vaccine.2025.127960

Source records